(HealthDay): A new and expensive antifungal drug to treat vaginal yeast infections was approved this week by the U.S. Food and Drug Administration, but critics say it’s not necessary.
Brexafemme (ibrexafungerp) is a one-day oral treatment and the first in a new class of triterpenoid antifungal drugs. The drug kills candida, the yeast which causes a vaginal infection, according to the drug manufacturer SCYNEXIS, The New York Times reported. The current standard oral drug, Diflucan (fluconazole), inhibits yeast growth but does not kill it.
“This approval of a new antifungal drug provides an additional treatment option for patients with vulvovaginal candidiasis or vaginal or vulvar yeast infections, and represents another step forward in the FDA’s overall efforts to ensure safe and effective efficacy. antifungal drugs are available to patients, ”Sumathi Nambiar, MD, MPH, director of the FDA’s Antiinfections Division, said in a statement.
But price is an issue. The estimated list price for a Brexafemme four-tablet treatment will range from $ 350 to $ 450, said David Angulo, MD, medical director of SCYNEXIS. The average retail price of fluconazole on GoodRx is $ 29.81 Time reported. It is not clear what the new drugs it is even needed, added Denise Jamieson, MD, MPH, president of gynecology and obstetrics at Emory University School of Medicine in Atlanta. “I don’t see a lot of resistance,” he told Time. “I really can’t comment on whether this will be a big addition or not. It’s always helpful to have another option, and then you’ll have to consider aspects like cost and tolerability.”
A clinical trial used to support FDA approval showed 50% efficacy at 10 days after treatment and 60% at 25 days after treatment Time was reported and another trial showed 64% efficacy on day 10 and 73% on day 25.
New York News Article
Copyright © 2021 HealthDay. All rights reserved.
Citation: New FDA-approved vaginal yeast infection drug (2021, June 4), retrieved June 5, 2021 at https://medicalxpress.com/news/2021-06-drug-vaginal-yeast-infections -fda.html
This document is subject to copyright. Apart from any fair treatment for private study or research purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.